Key result
Tolvaptan therapy in hospitalized heart failure patients resulted in higher average urine output in those with hypoalbuminemia compared to those without.
Why the study?
Does tolvaptan improve urine output in hospitalized heart failure patients with hypoalbuminemia compared to those without?
Cohort (n=40)
Does tolvaptan improve urine output in hospitalized heart failure patients with hypoalbuminemia compared to those without?
Tolvaptan added to loop diuretics significantly increases urine output in hospitalized heart failure patients, with a more pronounced effect in those with hypoalbuminemia.
Answers are grounded in this paper and cite their sources.
Tolvaptan may augment urine output more in hypoalbuminemic HF inpatients; hypothesis-generating and should not yet change practice.
BACKGROUND: Heart failure (HF) with hypoalbuminemia is associated with poor response to conventional therapy. We investigated whether tolvaptan, a potent aquaretic agent, might be of benefit in HF patients with hypoalbuminemia. METHODS: We prospectively enrolled 40 patients hospitalized for HF. Patients received conventional therapy including loop diuretics. We subsequently added tolvaptan in the range of 3.75-15 mg daily and it was discontinued after improvement of HF symptoms. We compared clinical and laboratory data in HF patients with and without hypoalbuminemia (defined as serum albumin <3.0 g/dL). RESULTS: Tolvaptan was administered in 18 HF patients with hypoalbuminemia (Group A) and 22 HF patients without hypoalbuminemia (Group B). The mean serum albumin was 2.63 ± 0.27 and 3.46 ± 0.25 g/dL, respectively. The average urine output on tolvaptan increased significantly in both groups (1644.4 ± 797.6-3011.6 ± 1453.8 mL/day, P = 0.004; 1459 ± 612.7-2112.2 ± 724.5 mL/day, P = 0.008; respectively). In addition, we observed higher urine output on therapy in Group A than in Group B (P = 0.015). There was a moderate negative correlation between serum albumin and average urine output on tolvaptan (r = -0.42, P = 0.007). CONCLUSIONS: The addition of tolvaptan to low dose loop diuretics might be an effective strategy for treatment of HF patients with hypoalbuminemia.
No takes yet. Share an insight, caveat, or question.
Okabe et al. (2015) conducted a cohort in Congestive Heart Failure (n=40). Tolvaptan in patients with hypoalbuminemia vs. Tolvaptan in patients without hypoalbuminemia was evaluated on Average urine output on therapy (p=0.015). Tolvaptan therapy in hospitalized heart failure patients resulted in higher average urine output in those with hypoalbuminemia compared to those without.
Synapse has enriched 10 related papers. Consider them for comparative context: